retatrutide fat loss trial Substack Series 3 of 6: – The Next Frontier in Longevity and Metabolic Health Eli Lilly's retatrutide shows promising

& Asano, K

Evidence references ADJUNCT ONE, PMID 27506222 ADJUNCT TWO, PMID 27493132 ADJUST T1D, PMID 40550013 Semaglutide crossover study, PMID 39794615 Tirzepatide observational data (Shah 2024), PMC11571402 Shah discontinuation post-hoc (ADJUNCT I/II), PMID 39717993 Shah 2025, GLP-1RA / tirzepatide in T1D with severe early (genetic) obesity ( JDST ) Insulin titration paper, PMID 39829697 Adjunct therapy review, PMID 40618954 Bone health review, PMC8118128 Weight loss and bone, PMID 38916894 Consensus and guidelines: ADA Standards 2025, PMID 39651989 ISPAD 2024, PMID 39657603 GLP-1 AID consensus, PMID 39517127 Related reading on GNL This Episode 17 conversation was the inspiration for the four-part Adjunctive Therapies guide built on top of the April 2026 evidence update

In cagrilintide, 2.4 mg in combination with semaglutide 100% of participants reported decreased appetite, 82% of participants on cagrilintide 4.5 mg versus 58% in placebo in combination with semaglutide 2.4 mg

And ensure at least 3 months effect

Fairly low side effects generally only lasting the day after injection